Cogstate Limited (ASX: CGS) - ETF Exposure

Current share price for CGS : $2.930 0.2 (7.33%)⁺

Cogstate Limited (CGS) is an ASX-listed company and is held by a number of exchange traded funds (ETFs). It is a Company that is engaged in creation, validation and commercialisation of digital brain health assessments; and design and provision of quality assurance services in clinical trials, focused on the administration, scoring and recording of conventional brain health assessments.

CGS General Information ⁺

ASX Code	CGS
Website	N/A
Industry/Sector	Health Care Technology
Market Cap ($M)	497
CGS Share Price	$2.930
Day High	$2.950
Day Low	$2.690
Last Close	$2.730
CGS Share Price Movement	$0.20 ( 7.33% )

Prices as at 16:40, 19 Aug 2026

⁺Security prices are delayed by at least 20 minutes and are indicative only.

Already own an Australian ETF? You may already have meaningful exposure to CGS

Cogstate Limited (CGS) is held across 2 ETFs spanning strategies that include health care technology exposure . Its weighting in those funds means performance can have an outsized influence - when CGS moves, funds like ATEC and DACE that hold it can move with it.

For more concentrated exposure, ETFs such as ATEC (BetaShares S&P/ASX Australian Technology ETF) allocate about 0.3% to CGS , while the average exposure across all 2 ETFs that hold it is around 0.1% .

Top ETF holdings

BetaShares S&P/ASX Australian Technology ETF (ATEC) ~ 0.3%
Dimensional Australian Core Equity (Managed Fund) (DACE) ~ 0%

Last updated: ETF data and holdings as at 19 August 2026

Own CGS directly or through an ETF?

How does holding Cogstate Limited (CGS) shares directly compare to ETFs that include it?

	CGS Direct	ATEC ASX	DACE ASX
Holdings	1 company	46 holdings	470 holdings
CGS Weight	100%	0.3%	0%
Diversification	Single Stock	Broad	Broad
Annual Cost	Brokerage only	0.48% p.a.	0.28% p.a.
Approx. Yield	1.5%	1.75%	2.97%
Star Ratings	-

Yields and costs are approximate. ETF yields reflect the fund's dividend distributions, not CGS's direct yield. Annual cost uses each ETF's MER.

CGS Exposure on $10,000 investment

How a $10,000 investment in Cogstate Limited (CGS) one week ago compares with ETFs that hold it.

Security	Investment type	Current price	7-day price movement	Dollar change	Value today
Cogstate Limited (CGS)	Direct share	$2.930	8.52%	+$852	$10,852
BetaShares S&P/ASX Australian Technology ETF (ATEC)	Equity - Australia Sectors	$23.600	-1.67%	-$167	$9,833
Dimensional Australian Core Equity (Managed Fund) (DACE)	Equity - Australia Strategy	$19.210	-1.84%	-$184	$9,816

Assumes $10,000 invested 7 days ago. Figures are based on price movement only and exclude distributions, fees and brokerage.

Cogstate Limited (CGS) ETFs

2 ETFs hold Cogstate Limited (CGS).

ETF	CGS Weight	MER	Yield
BetaShares S&P/ASX Australian Technology ETF (ATEC)	0.3%	0.48%	1.75%
Dimensional Australian Core Equity (Managed Fund) (DACE)	0%	0.28%	2.97%

Cogstate Limited (CGS) Upcoming Dividends & Yields

Distribution Type	Dividend	Franking	Ex-dividend date	Payment date	Current Price⁺	Price 7D Avg	Dividend Yield
HFResult	2¢	100%	27 Aug 2025	29 Sep 2025	-	-	-

See all dividends from Cogstate Limited (CGS) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

Cogstate Limited (CGS) price-sensitive announcements

CGS - FY26 Results Investor Briefing

Cogstate Limited reported significant growth in FY26 with a 15% increase in revenue, reach

Cogstate Limited (CGS)
18 Aug 2026 | 8:19 AM

CGS - FY26 Financial Results and Operational Update

Cogstate Limited reported a record financial performance for FY26, driven by substantial g

Cogstate Limited (CGS)
18 Aug 2026 | 8:13 AM

CGS - FY26 Appendix 4E

The Appendix 4E for Cogstate Limited for the fiscal year ending 30 June 2026, highlights a

Cogstate Limited (CGS)
18 Aug 2026 | 8:12 AM

CGS - Cogstate 4Q26 and FY26 Business Update

Cogstate Limited, a global leader in neuroscience endpoint innovation, reported its financ

Cogstate Limited (CGS)
8 Jul 2026 | 8:25 AM

Cogstate Limited (CGS) Recent ASX Announcements

Company	Sector	Market Cap ($m)	Headline	Release date/time⁺	Price at release⁺	Current price⁺	Gain/Loss
Cogstate Limited (CGS) ORDINARY FULLY PAID	Health Care	$498	FY26 Results Investor Briefing	18 Aug 2026 8:19AM	$2.790	$2.930	risen by 5.02%
Cogstate Limited (CGS) ORDINARY FULLY PAID	Health Care	$498	FY26 Financial Results and Operational Update	18 Aug 2026 8:13AM	$2.790	$2.930	risen by 5.02%
Cogstate Limited (CGS) ORDINARY FULLY PAID	Health Care	$498	Dividend/Distribution - CGS	18 Aug 2026 8:12AM	$2.790	$2.930	risen by 5.02%
Cogstate Limited (CGS) ORDINARY FULLY PAID	Health Care	$498	FY26 Annual Report	18 Aug 2026 8:12AM	$2.790	$2.930	risen by 5.02%
Cogstate Limited (CGS) ORDINARY FULLY PAID	Health Care	$498	FY26 Appendix 4E	18 Aug 2026 8:12AM	$2.790	$2.930	risen by 5.02%
Cogstate Limited (CGS) ORDINARY FULLY PAID	Health Care	$498	FY26 App 4G and Corporate Governance Statement	18 Aug 2026 8:12AM	$2.790	$2.930	risen by 5.02%

CGS Financial Summary

Year to Jun	NPAT	EPS	EPS chg (%)	PER	DPS	Yield (%)	Franking (%)
2028F	C2	$14.50	21.40%	20.20	6.50	2.20%	0.0%
2027F	C2	$12.00	22.30%	24.50	4.80	1.70%	0.0%
2026A	$17.32	$9.80	9.80%	23.00	5.80	2.60%	100.0%

CGS Peer Comparison

Company	Mkt Cap	EPS Growth (%)			P/E (%)			Dividend Yield (%)
Company	Mkt Cap	2026 A	2027 F	2028 F	2026 A	2027 F	2028 F	2026 A	2027 F	2028 F
4DMedical Limited (4DX)	$2,256M	0.3304	0.0000	0.0000	0.0000	0.0000	0.0000	0.00%	0.00%	0.00%
Cogstate Limited (CGS)	$464M	0.7148	0.0551	0.2428	30.6742	29.0735	23.3933	0.73%	1.20%	1.51%
Pro Medicus Limited (PME)	$20,554M	1.3034	-0.2940	0.2554	77.5828	109.8978	87.5417	0.35%	0.47%	0.58%

CGS Directors

Name	Position	Start Date
Mr Bradley O'Connor	Chief Executive Officer, Managing Director	1 Dec 2005
Mr Martyn Kenneth Myer	Non-Executive Chairman, Non-Executive Director	1 Oct 1999
Mr Darryl Noel Inns	Non-Executive Director	1 May 2026
Ms Ingrid Anne Player	Non-Executive Director	30 Aug 2019
Dr Richard Mohs	Non-Executive Director	20 Jan 2017
Ms Kim Wenn	Non-Executive Director	30 Nov 2020

Cogstate Limited (CGS) Changes in Directors' Interest & Trades

Date of change	Director	Buy/Sell	Security Type	Qty	Trade Price	Value
20 May 2026	WENN, Kim	Buy	Indirect Shares	4,030	$2.507	$10,105.200
15 Dec 2025	WENN, Kim	Buy	Indirect Shares	10,183	$2.186	$22,259.800
31 Oct 2025	O'CONNOR, Bradley	Issued	Related Securities	591,822	$1.770	$1,047,525.940

See all changes in directors' interest & trades for Cogstate Limited (CGS) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

CGS Management

Name	Position
Darren Watson	Chief Financial Officer
Darren Watson	Chief Financial Officer,Joint Company Secretary
Pam Ventola	Chief Science Officer
David James Franks	Company Secretary
Rachel Colite	Executive Vice President, Clinical Trials

CGS Substantial Shareholders

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Cogstate Limited (CGS). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.

Holding	Name
28,567,640 (16.90%)	David Dolby
23,714,566 (14%)	Myer, Martyn Kenneth
17,999,016 (10.70%)	Australian Ethical Investment
14,009,827 (8.30%)	Anacacia Pty Limited

CGS Calendar of Events

Date	Event
17 August 2027	Report (Annual)
17 August 2027	Report (Prelim)
18 February 2027	Report (Interim)
22 September 2026	Div Pay Date
24 August 2026	Books Close
21 August 2026	Div Ex Date

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.

What our members say about us